Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13%, depending on ...

Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

After radiologist Marie-Pierre lost her cousin to lung cancer, a screening helped to catch her own cancer early. Discover the ...

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

It's not only due to smoking, as this survivor's story might help demonstrate—says one expert doctor: "All you need to be at ...

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continu ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...